Professor Xu Ruihua: Precise, standardized, innovation -List of Annual Meeting of the Expert Committee of CSCO colorectal cancer in 2022

*For medical professionals for reading reference

What is the direction of CSCO's development planning and progress? How can "Chinese Voice" sing the world further?

Since its establishment, the my country Clinical Oncology Society (CSCO) colorectal cancer expert committee has made outstanding contributions to the development of colorectal cancer (CRC) diagnosis and treatment in China. The annual updated CSCO clinical diagnosis and treatment guide has also become an important basis for the implementation of the standardized diagnosis and treatment of clinicians in my country. In 2021, Professor Xu Ruihua of the Sun Yat -sen University Cancer Prevention and Control Center was elected as the chairman of the CSCO colorectal cancer expert committee. In addition to busy clinical work, he assumed a lot of important tasks in the Society. On the occasion of the annual meeting of the 2022 CSCO colorectal cancer expert committee, the "medical community" invited Professor Xu Ruihua to express his personal point of view on the prospects of the CRC diagnosis and treatment and the Expert Committee of CSCO colorectal cancer.

The CSCO colorectal cancer special committee is established to improve the domestic CRC diagnosis and treatment level

In 2017, the CSCO colorectal cancer expert committee was formally established. After that, the expert committee updated the CSCO guide based on the latest international research progress and the approval of drugs every year, and conducted a large number of tours across the country.

Professor Xu Ruihua

The CSCO colorectal cancer expert committee is a second -level society affiliated to CSCO. The main purpose is to provide multi -disciplinary, high -quality academic exchange platforms for clinical doctors engaged in clinical and basic research in CRC, and promote the CRC field "prevention, diagnosis, treatment "Innovation breakthroughs, further promoting and deepening the concepts of deepening and standardization, individualization and multidisciplinary cooperation across the country will help popularize the concept of early diagnosis and early treatment of CRC, promote the center of gravity of medical work, and sink the medical resources. In the end The level of CRC diagnosis and treatment in my country has been improved and contributed to improving the level of CRC's comprehensive diagnosis and treatment.

CSCO has never stopped in promoting industry progress and improving my country's standardized diagnosis and treatment level.

Professor Xu Ruihua

In recent years, CSCO has carried out thousands of various types of meetings, covering academic progress and science of disease, and played an important role in the "prevention, diagnosis, treatment, and recreation" of tumors. Both have benefited a lot. In addition, CSCO members often delivered academic speeches on behalf of Chinese groups at home and abroad, and published heavy research on international authoritative journals. CSCO has gradually developed into a tumor professional committee that attracts global professional scholars and has global influence.

Not only that, the CSCO guide is an operating suggestion to guide clinical intervention decisions, and it is an important reference basis for clinical standardized diagnosis and treatment and medical insurance system. China ’s medical development is unbalanced due to the vast regional medical development, and the clinical diagnosis and treatment practice of tumors requires both regional development differences, the availability of drugs and diagnosis and treatment methods, and guidance of guidelines. Further improve the diagnosis and treatment specifications and levels of grassroots doctors, pass the full management concept of patients with CRC, improve the quality of survival of patients, and be well received by the industry.

The annual meeting of the 2022CSCO colorectal cancer special committee is held, and the academic symphony at home and abroad plays academic symphony

From July 15th to 17th, 2022, the annual meeting of the CSCO colorectal cancer expert committee was successfully held in Guangzhou. The conference brings together well -known experts in the international and domestic CRC field and build a bridge for communication and exchanges between domestic and foreign experts, which will help strengthen the cooperation of domestic and foreign experts. The meeting focused on the precise diagnosis and treatment of CRC, the latest progress and transformation cutting edge, and continued to overcome the difficulty of CRC diagnosis and treatment.

In the field of CRC, the test of small residual lesions (MRDs) has attracted widespread attention from clinical experts in recent years, and it is expected to develop or even change the diagnosis and treatment path of CRC.

Professor Xu Ruihua

MRD has been used in many aspects of clinical, including relapse monitoring, prognosis estimates, treatment evaluation, etc., and has a relatively large application prospect. Circular tumor DNA (CTDNA) test is a promising alternative strategy that can directly evaluate peripheral blood to find MRD evidence. 2022 The latest report of the U.S. Clinical Oncology Society (ASCO) conference has a random control test based on CTDNA testing for postoperative colon cancer. Essence The annual meeting of the CSCO colorectal cancer expert committee has designed special MRD colleges to share the cutting -edge progress of MRD in the CRC field. I hope that in the future, data can be accumulated through large samples to formulate industry standards and bring better guidance to patients. In recent years, targeted therapy has emerged in the field of most malignant tumors, and its development in the field of CRC diagnosis and treatment is even more rapid.

Professor Xu Ruihua

A variety of targeted drugs such as 靶 ibinib have been included in the CSCO guide, and the median unpaid survival period (PFS) of patients with advanced CRC patients in the third -tier and above treatment [2]. In the current practical application of clinical clinical, cosinib has also showed good security. Based on this, Patinib was successfully approved in my country in 2018, and it is now widely used in the third -line CRC three -line and backline treatment.

The road of colorectal cancer targeted therapy exploration is far away

For many CRC patients after the treatment of second -tier standards, the progress of tumor is still unavoidable. It is urgent to effectively require effective third -line and above treatment solutions. In this regard, antemlodia production drugs such as vasinib showed good in the third -line treatment CRC. Efficacy.

Professor Xu Ruihua

With the continuous expansion of clinical studies, it is expected that the future of antibrokers can be combined with chemotherapy, immunotherapy and other anti -tumor therapy, which aims to further improve the efficacy. Fortunately, the preliminary research results of the combined treatment of anti-vascular production drugs and PD-1 inhibitors have shown satisfactory results and safety, bringing a new clinical treatment strategy to CRC patients. In addition, with the further announcement of the research results of antibodium -generating drugs combined with immunotherapy, it is also expected to move the front forward to patients with advanced CRC patients in the first -tier treatment.

At present, the clinical trial data of the Chinese population only in the Chinese population will also conduct more clinical trials to evaluate the efficacy and safety of oginib in other people, and look forward to the future design and implementation aimed at identifying molecules Biomators to predict the test of 替 替 替 生, allowing clinical medications of CRC patients to the era of precise treatment.

references:

[1] Tie J, Cohen JD, Lahouel K, Et Al. Circulating tumor dNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N English. 2022; 2261-2272.

[2] Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496 Then, then, then

Expert Introduction

Professor Xu Ruihua

Ph.D., professor, doctoral supervisor, and chief expert of colorectal cancer

Director of Sun Yat -sen University Tumor Prevention and Treatment Center, Director of the Institute, Director of the State Key Laboratory of South China Oncology, Director of the Coordinated Innovation Center of the Provincial Ministry of Ministry of Ministry, and Director of the National New Medicine (Anti -Cancer Drug) Clinical Test Center

Selected into Nanyue Baijie Talent Training Project, National Ten million Talent Project, and National Health Family Planning Outstanding Contribution Middle -aged and Young Experts

Member of the Department of Biology and Medicine, Science and Technology of the Ministry of Education

Chairman of the China Clinical Oncology Society (CSCO)

Vice Chairman of China Anti -Cancer Association

Chairman of the Guangdong Anti -Cancer Association

The first chairman of the Chinese Anti -Cancer Association A targeted treatment committee

The chairman of the Chinese Anti -Cancer Association Chemotherapy Special Committee

Chairman of the Council of the Instal Cancer Professional Committee of the China Clinical Oncology Society

"Cancer Communications" editor -in -chief

National Food and Drug Administration (CFDA) drug review and consulting expert

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -